Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Vitamin E deficiency due to either malabsorption or metabolic anomaly can cause nerve problems due to poor conduction of electrical impulses along nerves due to changes in nerve membrane structure and function. In addition to ataxia, vitamin E deficiency can cause peripheral neuropathy, myopathies, retinopathy, and impairment of immune responses.
This changeover to ESPN was originally to begin with WrestleMania 42 in April 2026, but in August 2025, it was announced the deal had been moved up. NXT's PLEs continued to air on Peacock until March 15, 2026, with Peacock only maintaining the Saturday Night's Main Event (SNME) specials as well as replays of recent episodes of SmackDown until at least 2029 as well as exclusive documentaries; outside the US, SNME streams on YouTube. In January 2026, more countries merged under Netflix, while Sub-Saharan Africa and Japan remained on SuperSport and Abema, respectively. On April 1, 2026, the last four remaining countries that were still on the standalone WWE Network transitioned to Netflix, permanently shutting down the WWE Network after 12 years. After Peacock lost NXT's PLEs in March, one event streamed on YouTube in April before WWE began a new deal with The CW in June in which 20 NXT PLEs would air on The CW's linear channel, and then beginning in August, NXT's events also began simulcasting on ESPN's streaming service. On October 1, Japan merged under Netflix. In addition to ESPN, WWE's events are still made available on traditional PPV outlets in the United States. WWE also partnered with Fandango to broadcast PLEs in select theaters across the United States, beginning with the 2025 SummerSlam, which was initially exclusive to select Regal Cinemas, with events after SummerSlam expanding to other theater chains. In Canada, WWE's PLEs are available through Vu!, Shaw PPV, or SaskTel PPV, and was formerly shown in select locations of the Cineplex Entertainment chain.
The absence of plutonium-238 contamination in atmospheric and seawater sampling confirmed the assumption that the cask is intact on the seabed. The cask is expected to contain the fuel for at least 10 half-lives (870 years). The US Department of Energy has conducted seawater tests and determined that the graphite casing, which was designed to withstand reentry, is stable and no release of plutonium should occur. Subsequent investigations have found no increase in the natural background radiation in the area. The Apollo 13 accident represents an extreme scenario because of the high re-entry velocities of the craft returning from cis-lunar space (the region between Earth's atmosphere and the Moon). This accident has served to validate the design of later-generation RTGs as highly safe. Mars 96 was launched by Russia in 1996, but failed to leave Earth orbit, and re-entered the atmosphere a few hours later. The two RTGs onboard carried in total 200 g of plutonium and are assumed to have survived reentry as they were designed to do. They are thought to now lie somewhere in a northeast–southwest running oval 320 km long by 80 km wide which is centred 32 km east of Iquique, Chile.
Sources: en.wikipedia.org
Stock, sometimes called bone broth, is a savory cooking liquid that forms the basis of many dishes – particularly soups, stews, and sauces. Making stock involves simmering animal bones, meat, seafood, or vegetables in water or wine, often for an extended period. Mirepoix or other aromatics may be added for more flavor.
Dexamethasone is a fluorinated glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease (COPD), croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome (a complication of some forms of cancer), and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days. The long-term use of dexamethasone may result in thrush, bone loss, cataracts, easy bruising, or muscle weakness. It is in pregnancy category C in the United States, meaning that it should only be used when the benefits are predicted to be greater than the risks. In Australia, the oral use is category A, meaning it has been frequently used in pregnancy and not been found to cause problems to the baby. It should not be taken when breastfeeding. Dexamethasone has anti-inflammatory and immunosuppressant effects. Dexamethasone was first synthesized in 1957 by Philip Showalter Hench and was approved for medical use in 1958. It is on the World Health Organization's List of Essential Medicines.
Schiller (1969), lawyer, co-founder of Boies Schiller Flexner LLP Eric Eisner (1970), lawyer, former president of The Geffen Company and founder of the Young Eisner Scholars program William Barr (1971), attorney general of the United States Arthur Engoron (1971), judge presiding over the New York civil investigation of The Trump Organization Arthur Helton (1971), lawyer, refugee advocate Gerard E. Lynch (1972), judge of the United States District Court for the Southern District of New York Gary Stephen Katzmann (1973), judge on the United States Court of International Trade Robert Katzmann (1973), judge of the United States Court of Appeals for the Second Circuit Eric Holder (1973), United States attorney general under Barack Obama, deputy attorney general under Bill Clinton, United States Attorney for the District of Columbia, judge of the Superior Court of the District of Columbia Jonathan Cuneo (1974), lawyer, founding partner of Cuneo Gilbert & LaDuca, LLP Abbe Lowell (1974), partner at Chadbourne & Parke, chief minority counsel during the Impeachment of Bill Clinton Jeffrey L. Kessler (1975), co-chairman of Winston & Strawn; former global litigation chair at Dewey & LeBoeuf Douglas Letter (1975), general counsel to the United States House of Representatives since 2018 J. Richard Cohen (1976), former president of the Southern Poverty Law Center Joseph A. Greenaway Jr.
Absorption of exudate, to regulate the moisture level surrounding the wound- for example, dry gauzes absorb exudate strongly, drying the wound, hydrocolloids maintain a moist environment and film dressings do not absorb exudate; Gas permeability and exchange, especially with regard to oxygen and water vapour; Maintaining the optimum temperature to encourage healing; Mechanically debriding a wound to remove slough. Pressure dressings are commonly used to treat burns and after skin grafts. They apply pressure and prevent fluids from collecting in the tissue. Dressings can also regulate the chemical environment of a wound, usually with the aim of preventing infection by the impregnation of topical antiseptics. Commonly used antiseptics include silver and DACC,povidone-iodine, boracic lint dressings or historically castor oil. Antibiotics are also often used with dressings to prevent bacterial infection. Medical grade honey is another antiseptic option, and there is moderate evidence that honey dressings are more effective than common antiseptic and gauze for healing infected post-operative wounds. Bioelectric dressings can be effective in attacking certain antibiotic-resistant bacteria and speeding up the healing process. Dressings are also often impregnated with analgesics to reduce pain. The physical features of a dressing can impact the efficacy of such topical medications. Occlusive dressings, made from substances impervious to moisture such as plastic or latex, can be used to increase their rate of absorption into the skin.
Sources: en.wikipedia.org
In 1415, during the last phase of the Hundred Years' War, the Shroud was removed from the church of Lirey with the intention of depositing it temporarily at the castle of Montfort for safekeeping. Marguerite de Charny, the granddaughter of the knight who had endowed the church of Lirey, then took possession of the cloth and exhibited it at the church of Saint-Hippolyte, Doubs. Marguerite's refusal to return the Shroud to Lirey led to litigation. She carried the Shroud in traveling exhibitions, including to Chimay and Mons. In 1453 Marguerite deeded the Shroud to Louis, Duke of Savoy. For having sold the Shroud and disregarded the rights of the canons of Lirey, Marguerite was excommunicated by the curia of Besançon in 1457. The Shroud became the palladium of the House of Savoy, and by 1466 it had been deposited in the ducal chapel in Chambéry, the capital of the Savoyard state. In 1506 Pope Julius II authorized the veneration of the Shroud as a true relic of Jesus. In 1532 the Shroud was damaged by a fire in the chapel of Chambéry, when molten silver from the reliquary passed through the layers of folded cloth, leaving a symmetrical pattern of holes in the unfolded Shroud but without doing much damage to the image areas. The Poor Clare nuns in Chambéry later sewed patches over those holes. In 1578 Emmanuel Philibert, Duke of Savoy ordered the cloth to be brought to Turin, the new Savoyard capital, and it has remained in Turin ever since.
== Pathophysiology == Hemoglobin H disease is a genetic disorder resulting in absent or impaired production of the α-globin protein, a normal component of the hemoglobin. The disease occurs when the α-globin gene expression is reduced to less than 30% of the normal expression. In a healthy individual there are four copies of the gene which encode the α-globin protein. α-globin is encoded by the HBA1 (2 copies) and HBA2 (2 copies) genes. The genotype of healthy individuals with four normal copies of α-globin is annotated as αα/αα. In individuals with deletional HbH disease, there is deletion of three of the four α-globin alleles, which is annotated as --/-α. Non-deletional HbH disease refers to a decreased α-globin that has not occurred as a result of the complete deletion of the DNA sequences encoding HBA1 and HBA2, and this is more rare than the deletional type. The most common hemoglobin found within adult red blood cells is hemoglobin A. The structure of HbA consists of two α-globin chains bound to two β-globin chains to form a tetramer (a protein made up four protein chains). When there is lower than normal production of α-globin, as in HbH disease, the excess β-globin form β4-tetramers, termed hemoglobin H. These β4-tetramers accumulate in red blood cells and precipitate to form HbH inclusion bodies. The inclusion bodies in the mature red blood cells are removed by the spleen and this results in an early destruction of these red blood cells. This destruction of red blood cells by the spleen is termed extravascular hemolysis.
=== Saturday Night Live === In September 2005, Samberg joined Saturday Night Live as a featured player and writer. Though his live sketch roles were limited in his first year, he appeared in many prerecorded sketches including commercial parodies and various other filmed segments. On December 17, 2005, he co-starred with castmate Chris Parnell in the Digital Short show "Lazy Sunday," a hip hop song about a quest to see the film The Chronicles of Narnia: The Lion, the Witch and the Wardrobe. The short became an Internet phenomenon and garnered Samberg significant media and public attention. Acclaim continued, especially for "Dick in a Box," a duet with Justin Timberlake that won a Creative Arts Emmy for Outstanding Original Music and Lyrics. The video for his comedy troupe's collaboration with T-Pain, "I'm on a Boat," had over 56 million views on YouTube, after debuting on February 7, 2009. The song was nominated for a Grammy Award. Another digital short, "Motherlover," also featuring Timberlake, was released on May 10, 2009, to commemorate Mother's Day. Outside of his prerecorded segments, he participated in recurring live segments, such as his Blizzard Man sketch. On June 1, 2012, Samberg's spokesperson announced that Samberg had left the show. He returned to the show to host the Season 39 finale in 2014 and to star in the 40th anniversary special's Digital Short. He later returned in Season 50 to portray Doug Emhoff in the run up to the 2024 election, as well as providing some additional Digital Shorts.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.